Skip to main content
Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.
Partnership
1 min read

Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

Aspect Biosystems
Aspect Biosystems

Platform

Originally reported by 3DPrint.com

Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes. Building on a 2.6 billion dollar framework, this new phase adds equity investment to scale microfluidic biomanufacturing. This represents a systemic shift for the AM industry, moving from mechanical implants to functional biological cures for the 11 percent of the population with diabetes. 🧬🏥 #3DPrinting #Bioprinting #Diabetes #Pharma #Innovation

Explore Aspect BiosystemsRead Original

How This Connects

6 related events
  1. Company story

    Aspect Biosystems secures $280M to scale bioprinted tissue therapy production in Canada.

  2. Same pattern

    Washington State University researchers developed the first fully synthetic, 3D-printed beating heart model for surgical rehearsal.

  3. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  4. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  5. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  6. This article

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.